Ken G Andersson
Overview
Explore the profile of Ken G Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlein E, Andersson K, Dallas T, Syvanen S, Sehlin D
MAbs
. 2024 Apr;
16(1):2339337.
PMID: 38634473
Recent development of amyloid-β (Aβ)-targeted immunotherapies for Alzheimer's disease (AD) have highlighted the need for accurate diagnostic methods. Antibody-based positron emission tomography (PET) ligands are well suited for this purpose...
2.
Bonvicini G, Bagawath Singh S, Nygren P, Xiong M, Syvanen S, Sehlin D, et al.
Anal Biochem
. 2023 Nov;
686:115406.
PMID: 38006952
Despite years of utilizing the transferrin receptor 1 (TfR1) to transport large biomolecules into the brain, there is no consensus on how to optimally measure affinity to it. The aim...
3.
Gustavsson T, Metzendorf N, Wik E, Roshanbin S, Julku U, Chourlia A, et al.
Alzheimers Res Ther
. 2023 May;
15(1):90.
PMID: 37131196
Background: Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer's disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting...
4.
Bonvicini G, Syvanen S, Andersson K, Haaparanta-Solin M, Lopez-Picon F, Sehlin D
Transl Neurodegener
. 2022 Dec;
11(1):55.
PMID: 36567338
Background: Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood-brain barrier (BBB). Such ligands are more sensitive and...
5.
Oroujeni M, Xu T, Gagnon K, Rinne S, Weis J, Garousi J, et al.
Pharmaceutics
. 2021 Mar;
13(2).
PMID: 33672373
Epidermal growth factor receptor (EGFR) is overexpressed in many malignancies. EGFR-targeted therapy extends survival of patients with disseminated cancers. Radionuclide molecular imaging of EGFR expression would make EGFR-directed treatment more...
6.
Garousi J, Huizing F, Vorobyeva A, Mitran B, Andersson K, Leitao C, et al.
Sci Rep
. 2019 Oct;
9(1):14907.
PMID: 31624303
Carbonic anhydrase IX (CAIX) is a cancer-associated molecular target for several classes of therapeutics. CAIX is overexpressed in a large fraction of renal cell carcinomas (RCC). Radionuclide molecular imaging of...
7.
Rosestedt M, Andersson K, Rinne S, Leitao C, Mitran B, Vorobyeva A, et al.
Sci Rep
. 2019 May;
9(1):6779.
PMID: 31043683
Human epidermal growth factor receptor type 3 (HER3) plays a crucial role in the progression of many cancer types. In vivo radionuclide imaging could be a reliable method for repetitive...
8.
Leitao C, Rinne S, Mitran B, Vorobyeva A, Andersson K, Tolmachev V, et al.
Int J Mol Sci
. 2019 Mar;
20(5).
PMID: 30832342
Affibody-based imaging of HER3 is a promising approach for patient stratification. We investigated the influence of a hydrophilic HEHEHE-tag ((HE)₃-tag) and two different gallium-68/chelator-complexes on the biodistribution of Z with...
9.
Rinne S, Leitao C, Mitran B, Bass T, Andersson K, Tolmachev V, et al.
Sci Rep
. 2019 Jan;
9(1):655.
PMID: 30679757
Radionuclide molecular imaging of human epidermal growth factor receptor 3 (HER3) expression using affibody molecules could be used for patient stratification for HER3-targeted cancer therapeutics. We hypothesized that the properties...
10.
Oroujeni M, Garousi J, Andersson K, Lofblom J, Mitran B, Orlova A, et al.
Cells
. 2018 Sep;
7(9).
PMID: 30231504
Dfo-zegfr: 2377 was efficiently (isolated yield of 73 ± 3%) and stably labeled with Ga. Binding of [Ga]Ga-DFO-ZEGFR:2377 to EGFR-expressing cells in vitro was receptor-specific and proportional to the EGFR...